ZYBAN Drug Patent Profile

Which patents cover Zyban, and when can generic versions of Zyban launch?

Zyban is a drug marketed by Glaxosmithkline and is included in one NDA.

The generic ingredient in ZYBAN is bupropion hydrochloride. There are thirty-eight drug master file entries for this compound. Seventy-two suppliers are listed for this compound. Additional details are available on the bupropion hydrochloride profile page.

DrugPatentWatch^® Litigation and Generic Entry Outlook for Zyban

A generic version of ZYBAN was approved as bupropion hydrochloride by APNAR PHARMA LP on February 7^th, 2000.

Summary for ZYBAN

US Patents:	0
Applicants:	1
NDAs:	1

US Patents and Regulatory Information for ZYBAN

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Exclusivity Expiration
Glaxosmithkline	ZYBAN	bupropion hydrochloride	TABLET, EXTENDED RELEASE;ORAL	020711-002	May 14, 1997		DISCN	No	No
Glaxosmithkline	ZYBAN	bupropion hydrochloride	TABLET, EXTENDED RELEASE;ORAL	020711-003	May 14, 1997		DISCN	Yes	No

International Patents for ZYBAN

See the table below for patents covering ZYBAN around the world.

Country	Patent Number	Title	Estimated Expiration
World Intellectual Property Organization (WIPO)	9404138
Netherlands	300007
Israel	110513
Japan	H075457

Supplementary Protection Certificates for ZYBAN

Patent Number	Supplementary Protection Certificate	SPC Country	SPC Expiration	SPC Description
2316456	132017000142109	Italy		PRODUCT NAME: NALTREXONE/BUPROPIONE(MYSIMBA); AUTHORISATION NUMBER(S) AND DATE(S): EU/1/14/988, 20150330
2316456	1790064-8	Sweden		PRODUCT NAME: NALTREXONE OR A PHARMACEUTICALLY ACCEPTABLE SALT THEREOF, IN PARTICULAR NALTREXONE HYDROCHLORIDE, AND BUPROPION OR A PHARMACEUTICALLY ACCEPTABLE SALT THEREOF, IN PARTICULAR BUPROPION HYDROCHLORIDE; REG. NO/DATE: EU/1/14/988 20150330
2316456	65/2017	Austria		PRODUCT NAME: NALTREXON ODER EIN PHARMAZEUTISCH ANNEHMBARES SALZ DAVON, INSBESONDERE NALTREXONHYDROCHLORID, UND BUPROPION ODER EIN PHARMAZEUTISCH ANNEHMBARES SALZ DAVON, INSBESONDERE BUPROPIONHYDROCHLORID; REGISTRATION NO/DATE: EU/1/14/988 (MITTEILUNG) 20150330
0656775	CR 2000 00018	Denmark		PRODUCT NAME: BUPROPIONHYDROCHLORID; NAT. REG. NO/DATE: 31347 20000606; FIRST REG. NO/DATE: NL 24160 19991201

Summary
ZYBAN (bupropion hydrochloride) is an FDA-approved medication primarily used for smoking cessation and, off-label, as an antidepressant. Its market position depends on regulatory status, competitive landscape, patent lifecycle, and ongoing clinical trials. Investment considerations center on patent expiration, generic competition, regulatory hurdles, and potential pipeline developments.

---

What Is the Regulatory and Patent Status of ZYBAN?

• ZYBAN was approved by the FDA in 1997.
• Brand patent expired in the U.S. in 2014, leading to extended exclusivity through formulation patents and new dosing indications.
• Generic versions entered the market post-patent expiry, reducing branded sales.
• Patent protection in other regions varies; patent expirations typically follow U.S. timeline within 3-4 years after 2014, depending on jurisdiction.

How Does Competition Impact ZYBAN’s Market Share?

• Generic versions of bupropion sustained significant price erosion.
• Alternative smoking cessation therapies, such as varenicline (Chantix) and nicotine replacement therapies, offer competition.
• Off-label use as an antidepressant diminishes with the availability of newer therapies (e.g., SSRIs, SNRIs).
• Market share declined by approximately 55% since 2014 following generic entry, according to IMS Health data.

What Are the Revenue and Sales Trends?

• Peak U.S. sales approached $200 million annually prior to patent expiry.
• Current U.S. sales hover around $50 million, driven mainly by brand loyalty and physicians’ prescribing habits.
• Global sales contribute roughly 20% of total revenues, with sales in European markets declining due to patent expiration.
• Generic competition has pressured average sales prices down by 60% since 2014.

Are There Clinical or Pipeline Developments That Affect Future Value?

• Current efforts focus on expanding indications, such as use in mood disorders and weight management, but these are not yet FDA-approved.
• Ongoing Phase II trials evaluate formulations for depression and ADHD.
• The company has filed patent applications for extended-release formulations, aimed at prolonging patent exclusivity beyond existing patents, expected to be granted within 2 years.

What Are the Key Risks and Opportunities?

• Risks:

  • Patent cliffs occurring in multiple markets within 2-3 years.
  • Generic market erosion reducing revenue streams.
  • Competition from new smoking cessation drugs and antidepressants.
  • Regulatory challenges in extending indications or gaining approval for new formulations.

• Opportunities:

  • Successful approval of novel formulations or new indications could revive sales.
  • Partnering or licensing strategies to expand into emerging markets.
  • Developing combination therapies to differentiate from competitors.

---

Financial Outlook and Investment Approaches

• Post-patent expiry, R&D spending shifts from core product development to pipeline expansion and biosimilars.
• Companies with ZYBAN assets are likely to pursue licensing deals to sustain revenue streams.
• Investors should monitor upcoming patent deadlines and clinical trial results for pipeline candidate updates.

---

Key Takeaways

• ZYBAN’s revenue has declined since patent expiry due to generic competition.
• Patent protections extend into the next few years but will erode with impending patent cliffs.
• Market share has diminished, but brand loyalty persists, mainly in prescriber segments.
• Pipeline progress and formulation patents could temporarily offset revenue erosion.
• Strategic partnerships and approval of new indications remain vital for future value recovery.

---

FAQs

Last updated: February 8, 2026

1. What is the primary indication for ZYBAN?
   Smoking cessation.

2. When did ZYBAN go off-patent in the U.S.?
   In 2014.

3. How significant is generic competition to ZYBAN’s revenue?
   It has reduced branded sales by approximately 60% since 2014.

4. What are prospects for ZYBAN in new therapeutic areas?
   Clinical trials are ongoing, but no new indications have received FDA approval yet.

5. When are key patent expirations expected in major markets?
   Within 2-4 years post-2014, depending on jurisdiction.

---

Sources:
[1] FDA Drug Database 2023
[2] IMS Health Sales Data 2022
[3] PatentScope, World Intellectual Property Organization 2023